5/9/2025

Janusmed kön och genus

Janusmed kön och genus – Zofran

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Ondansetron

Ondansetron

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther. 1992;51:51-5.

  2. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy. 1998;18:288-94.

  3. Zofran (ondansetron). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-06-01, cited 2023-06-13]

  4. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450-7.

  5. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting A multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990;113:834-40.

  6. Liaw CC, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol. 2003;26:12-5.

  7. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102:1094-100.

  8. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64:19-25e6.

  9. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron). Food and Drug Administration [www]. [cited 2015-01-14].

  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.

  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther. 1992;51:51-5.
  2. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy. 1998;18:288-94.
  3. Zofran (ondansetron). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-06-01, cited 2023-06-13]
  4. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450-7.
  5. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting A multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990;113:834-40.
  6. Liaw CC, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol. 2003;26:12-5.
  7. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102:1094-100.
  8. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64:19-25e6.
  9. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron). Food and Drug Administration [www]. [cited 2015-01-14].
  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]